, , , , ,

There is increasing recognition that treatment of common cancers can be modified according to a patient’s expected prognosis or response to therapy. For some new molecularly guided therapies, powerful biomarkers of response are available, which often comprise mutations in the specific protein that is targeted. However, for conventional cytotoxic therapies, predictive markers of response are rare. In view of the modest survival benefits that conventional cytotoxic therapies provide for patients with common solid malignancies, biomarkers of prognosis still have substantial potential clinical importance. Such markers…. continue reading https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30117-1/fulltext?rss=yes&utm_campaign=update-langas&utm_source=hs_email&utm_medium=email&utm_content=64671022&_hsenc=p2ANqtz–3x7BbKUQUEcItxHAiPkFWMOl-1N0ONRK561Zm6tftxX-MaE72LxbWw5YVJhFHjdmrqz5FmyeLJMIyoJ2SXyjpiCdS6w&_hsmi=64671022